Selvita S.A.
https://selvita.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Selvita S.A.
Poland’s Ryvu To Feed Galapagos’ R&D Effort
Ryvu Therapeutics has added to its drug discovery collaborators with an early-stage deal with Belgium’s Galapagos.
Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Inflection's Lead Series Boosts AUM's Oncology Pipeline
Asian oncology venture gains worldwide rights to novel molecule series from Inflection, giving a leg up to its global ambitions.
Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Services
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Fidelta d.o.o.